Current therapy and new molecular approa
✍
Thomas Hügle; Andreas Cerny
📂
Article
📅
2003
🏛
John Wiley and Sons
🌐
English
⚖ 159 KB
## Abstract Current therapeutic options for hepatitis C are limited, especially for genotype 1. For genotypes 2 and 3, pegylated interferon in combination with ribavirin, can lead to a sustained virological response in up to 80% of patients. Unfortunately, adverse effects of IFN and ribavirin are a